Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
- March 2016 •
- 160 pages •
- Report ID: 326190
Use this report to:
Examine leading and emerging competitors in the current worldwide CNS biomarkers market.
Investigate the introduction of combination therapies, which are expected to contribute substantially to market growth through the forecast period.
Assesses companies poised to introduce products during the forecast period and discuss how it will affect the competitive environment.
Examine the competitive environment with emphasis on how new products and technologies are influencing the current standard of care.
The global CNS biomarker market should reach nearly $5.1 billion by 2020 from $3.1 billion in 2015, a compound annual growth rate (CAGR) of 10.4% from 2015 to 2020.
The discovery application market should reach over $3.3 billion by 2020 from over $1.9 billion in 2015, a CAGR of 11.7% from 2015 to 2020.
The drug development application market should reach $776 million by 2020 from $303 million in 2015, a CAGR of 20.7% from 2015 to 2020.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop such a strategy begins where opportunity exists and ends with effective execution to capture profit from that opportunity.
The CNS biomarkers market presents the largest of all opportunities in representative disease sub segments. This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease segment.
Continued growth is expected in countries such as India, China, Brazil and Russia where a growing middle class is driving this growth. This report seeks to address and analyze the critically important areas of changing market dynamics, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to help companies allocate resources and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2014 to 2020) are discussed. New products approved in 2013 and 2014 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Figures for 2015 are estimated, except where actual results have been reported.
The report includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles are provided for current market leaders as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers’ level and are projected at the 2015 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category and company from 2015 through 2020. The study is arranged to offer an overview of the CNS biomarkers market accompanied by product, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each disease sub segment.
In general, excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.